First, separate the diagnosis question from the treatment question
An MDT discussion is only useful if everyone is answering the same question. For Parkinson's disease, there are at least two separate questions. The first is diagnostic: is this Parkinson's disease, a different parkinsonian syndrome, or a condition that mimics it? The second is therapeutic: given the diagnosis and the person's current symptoms, what are the realistic options now, and what should be reviewed later?
These questions need different evidence. A diagnostic discussion leans on the history, examination findings, imaging already performed and the response to treatment over time. A treatment discussion leans on the symptom pattern through the day, the timing and effect of current medicines, and the person's goals. If the referral does not state which question is being asked, the discussion can drift into general opinions that do not help the patient decide anything.
For an overseas patient, the practical point is that you should ask the receiving team to state, in writing, what question it understands you to be asking. That single clarification prevents a records-based review from being treated as a final diagnosis or a treatment plan when it is neither.
What the ON and OFF assessments actually need to show
ON and OFF describe how symptoms change in relation to levodopa and the person's medicine schedule. In an ON state, symptoms are usually better controlled; in an OFF state, they return or worsen. A useful discussion needs more than the words 'wears off' or 'fluctuates'. It needs a structured picture of when the person is ON, when they are OFF, how long each state lasts, and which symptoms change.
The reason this matters is that different symptoms respond differently. Some motor symptoms may improve with levodopa, while others may not. A discussion that only records 'good response' or 'poor response' cannot distinguish between a medicine-timing problem, a dose problem, or a symptom that is unlikely to improve with more levodopa. That distinction changes what options are worth considering.
Ask the team what format it wants for this information. A simple diary kept over several days, recording times of doses, times when symptoms return, and which symptoms are worst, is often more useful than a single clinic description. Do not change any medicine to create a particular state for assessment unless the treating clinician has instructed you to do so. The diary records what already happens; it is not a reason to alter treatment.
The discussion should also answer whether the ON/OFF pattern is stable enough to interpret. If the person has recently changed medicines, has an infection, or is not sleeping, the pattern may not represent their usual state. The team should say whether it considers the information adequate or whether it wants more.
Levodopa response: what the discussion must clarify
Levodopa response is central to Parkinson's care, but 'responds to levodopa' is not a single fact. The discussion should clarify which symptoms improve, how much they improve, how long the improvement lasts, and whether the improvement is consistent. It should also record what happens when the effect wears off.
This matters because a strong response in some symptoms does not automatically mean every symptom will respond. If the main disability comes from a symptom that does not improve with levodopa, then simply adjusting levodopa may not address the person's priority. The discussion should separate the symptoms that respond from those that do not, and say which of them are the main problem for the patient.
The team should also state what it cannot conclude from the records. A video or a clinic examination captures one moment. It may not show the pattern across a whole day. If the assessment is based on limited information, the discussion should say so and identify what additional information would change the conclusion.
For the patient, the practical question is: 'Based on what you have, which of my symptoms do you think are levodopa-responsive, and which are not?' The answer should be specific enough that you can compare it with your own experience.
Device-based treatment: what an MDT should and should not conclude
Deep brain stimulation uses implanted electrodes and a pulse generator. It may help selected Parkinson's symptoms, but it does not cure the disease. That description sets the boundary for what a discussion can reasonably conclude. It can consider whether device-based treatment is worth assessing further. It should not present the discussion itself as a decision to proceed.
A useful discussion should answer several specific questions. Which symptoms are being targeted? Are those symptoms the ones that have responded to levodopa? What has already been tried, and for how long? What does the person expect from treatment, and are those expectations realistic? What would make the team advise against proceeding?
It should also address the practical side. Who would perform the assessment and any procedure? Who would manage programming afterwards, and where? What follow-up would be needed, and can it be provided in the patient's home country or only in China? These are not administrative details to settle later; they determine whether the option is workable for this person.
The discussion should be explicit about uncertainty. It cannot guarantee that a device will be offered, that symptoms will improve, or that programming will be straightforward. If the team cannot answer the follow-up question, that is itself an important answer, because it affects whether travelling for assessment makes sense.
Follow-up and programming: the question patients forget to ask
Device-based treatment is not a one-off event. After implantation, the device needs adjustment, and the person needs ongoing Parkinson's care. A discussion that focuses only on whether the procedure is possible, without addressing who will manage the device afterwards, leaves the most important practical question unanswered.
Ask the team to describe, in general terms, what follow-up involves and who provides it. Ask whether adjustments can be made locally, whether the patient would need to return to China, and what happens if a problem arises between visits. Do not assume that any centre can adjust any device, or that remote support is available. These are questions for the named provider, not facts you can infer from a general description of the treatment.
The discussion should also clarify who is responsible for what. If the assessment happens in China and the person returns home, which clinician manages medicines, and which manages the device? If that division of responsibility is unclear, the patient can end up with no one coordinating care.
This is also where the limits of a records-based opinion matter. A review of records can comment on whether assessment seems reasonable. It cannot confirm that a device will be implanted, that programming will be available, or that follow-up will work in your circumstances. Those require direct confirmation from the providers involved.
What to ask the hospital before you rely on an MDT format
In China, the hospital decides whether it offers a multidisciplinary discussion, which specialties take part, and what records it requires. You should not assume that a discussion will be arranged, or that it will take a particular form. The way to find out is to ask directly, in writing, and to keep the answers.
Ask whether the hospital offers a multidisciplinary discussion for Parkinson's disease, and if so, which specialties would be involved. Ask what question the discussion would address, what records it needs, and whether the patient needs to travel for it. Ask what the output would be: a written opinion, a treatment plan, or a recommendation for further assessment. Ask who would communicate the result and in what language.
If the hospital does not offer this format, that is useful information. It means the decision may rest with one specialist rather than a group, and you should ask that specialist the same questions. A single clinician can still address diagnosis, levodopa response, device suitability and follow-up, provided the questions are clear.
It also helps to ask what the hospital's written estimate or plan includes, and what remains undecided. Scope varies between providers, so ask the named hospital how its own process works rather than relying on a general description. If you are comparing options, compare the same questions across providers.
For an initial enquiry, a brief summary is enough: the diagnosis or suspected diagnosis, the main question, and the current symptom pattern. You do not need to send a complete medical archive at the first contact. Records can be shared after the team explains what it needs.
A practical next step is to write down your three most important questions, ask the hospital whether it can answer them through a multidisciplinary discussion or a single specialist, and request the answer in writing. An initial enquiry through ChinaSpecialistCare is free and can help identify what information is missing before you decide whether to travel.
Sources & scope of this guide
References and official service information relevant to this guide.
This is general planning information and has not been individually reviewed by a doctor. Medical decisions and personal treatment advice come from your treating clinicians.